\n\n<\/span>India\u2019s Pharmaceutical Sector: a Need of Reform<\/strong><\/span><\/span><\/h2>\nGeneric medicines play a crucial role in improving healthcare accessibility in India, saving consumers approximately \u20b930,000 crores through government initiatives by 2024. Although bioequivalent to branded drugs, concerns over their quality persist. The existing regulatory framework, divided between the Central Drugs Standard Control Organisation (CDSCO) and State Drug Regulatory Authorities, enables some manufacturers to exploit regulatory gaps, compromising drug quality. Despite multiple committee recommendations since 1954, India has yet to implement centralized pharmaceutical regulation. This underscores the urgent need for comprehensive reforms to ensure both affordability and quality in the country’s pharmaceutical sector.<\/span><\/p>\nCurrent Status of Pharmaceutical Regulation in India<\/strong><\/span><\/h3>\nRegulatory Bodies<\/strong><\/span><\/p>\n\n- Central Drugs Standard Control Organization (CDSCO)<\/strong>:<\/span>
\nEstablished in 1940, CDSCO serves as the primary regulatory authority overseeing the pharmaceutical sector. It ensures that drugs, cosmetics, and medical devices meet safety, efficacy, and quality standards.<\/span><\/li>\n- Department of Chemicals and Petrochemicals (DCP)<\/strong>:<\/span>
\nFounded in 1991, the DCP is responsible for policy and planning related to chemicals, petrochemicals, and pharmaceuticals. It supports the sector’s growth and development.<\/span><\/li>\n- National Pharmaceutical Pricing Authority (NPPA)<\/strong>:<\/span>
\nCreated in 1994, the NPPA regulates the prices of essential medicines, ensuring affordability and accessibility. It also revises and updates the list of drugs under price control.<\/span><\/li>\n<\/ol>\nKey Policies and Regulations<\/strong><\/span><\/p>\n\n- Drug Price Control<\/strong>:<\/span>
\nThe Drugs Price Control Order (DPCO)<\/em>, first introduced in 1970, empowers the government to regulate the prices of 74 bulk drugs and their formulations. While it ensures affordability, direct pricing control can discourage pharmaceutical companies from producing certain drugs.<\/span><\/li>\n- Product Quality and Manufacturing Standards<\/strong>:<\/span>
\nThe CDSCO enforces Good Manufacturing Practices (GMP)<\/em> to ensure that pharmaceutical plants and materials meet stringent quality standards. The National Pharmaceutical Policy<\/em> further aims to strengthen GMP compliance across the sector.<\/span><\/li>\n- Patent and Intellectual Property Regulations<\/strong>:<\/span>
\nThe Patent Act, 1970<\/em> (amended in 2005) outlines provisions for drug patentability, royalty, generic drug production immunity, patent opposition, compulsory licensing, and export.<\/span>
\nTRIPS (Trade-Related Aspects of Intellectual Property Rights<\/em>) provides protection for undisclosed clinical trial data.<\/span><\/li>\n<\/ol>\nKey Regulatory Guidelines<\/strong><\/span><\/p>\n\n- Drugs and Cosmetics Act, 1940<\/strong>:<\/span>
\nGoverns the import, manufacture, distribution, and sale of drugs, cosmetics, and medical devices in India.<\/span><\/li>\n- Schedule M<\/strong>:<\/span>
\nDetails the general and specific requirements for factory premises, materials, and equipment used in drug manufacturing.<\/span><\/li>\n- Schedule T<\/strong>:<\/span>
\nPrescribes GMP specifications for the production of Ayurvedic, Siddha, and Unani medicines.<\/span><\/li>\n- Schedule Y<\/strong>:<\/span>
\nOutlines the legislative requirements for conducting clinical trials in India.<\/span><\/li>\n- Good Clinical Practice (GCP) Guidelines<\/strong>:<\/span>
\nDeveloped by the Ministry of Health, the DCGI, and ICMR, these guidelines are aligned with international standards like the Declaration of Helsinki<\/em> and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)<\/em>. They regulate clinical research involving human subjects.<\/span><\/li>\n- The Pharmacy Act, 1948<\/strong>:<\/span>
\nRegulates the education and practice of pharmacy in India.<\/span><\/li>\n- The Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954<\/strong>:<\/span>
\nProhibits advertisements that promote drugs with exaggerated or magical claims.<\/span><\/li>\n- The Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985<\/strong>:<\/span>
\nRegulates the manufacture, distribution, and use of narcotic drugs and psychotropic substances.<\/span><\/li>\n<\/ol>\n![\"\ud835\udc08\ud835\udc00\ud835\udc12\ud835\udc12\ud835\udc24\ud835\udc28\ud835\udc28\ud835\udc25:](\"https:\/\/triumphias.com\/blog\/wp-content\/uploads\/2024\/12\/WhatsApp-Image-2024-12-26-at-11.06.32-AM-113x150.jpeg\") <\/p>\n
Major Challenges Arising from Inadequate Pharmaceutical Regulation<\/strong><\/span><\/h3>\nChallenges in India’s Pharmaceutical Sector<\/strong><\/span><\/p>\n\n- Proliferation of Substandard and Counterfeit Drugs<\/strong>:<\/span>
\nWeak enforcement mechanisms allow low-quality and counterfeit drugs to infiltrate the market, compromising public health and eroding patient trust.<\/span><\/li>\n<\/ol>\n\n- This issue is particularly severe in low-income countries with minimal regulatory oversight, leading to higher morbidity and mortality rates.<\/span><\/li>\n
- In India, regulatory gaps and a fragmented market dominated by small manufacturers enable the production and distribution of substandard drugs.<\/span><\/li>\n
- Example<\/strong>: The World Health Organization (WHO) estimates that 10% of drugs in low- and middle-income countries are substandard or falsified. Additionally, WHO linked Indian-made cough syrups to acute kidney failure and fatalities among children in Gambia.<\/span><\/li>\n
- Erosion of International Trust in Exports<\/strong>:<\/span>
\nInconsistent adherence to global standards tarnishes the reputation of exporting countries, reducing their competitiveness in international markets.<\/span><\/p>\n\n- Regulatory lapses such as data fabrication and inadequate quality checks undermine confidence among global buyers.<\/span><\/li>\n
- This impacts long-term economic prospects for pharmaceutical-exporting nations like India.<\/span><\/li>\n
- Example<\/strong>: Since early 2022, Indian drug manufacturers have received over nine FDA warning letters, risking bans on new product exports to the U.S. The Ranbaxy scandal remains a notable case of international regulatory failure.<\/span><\/li>\n<\/ul>\n<\/li>\n
- Antimicrobial Resistance (AMR) Crisis<\/strong>:<\/span>
\nUnregulated antibiotic production and irrational use contribute significantly to the growing AMR crisis, a critical global health threat.<\/span><\/p>\n\n- AMR undermines healthcare systems by making common infections untreatable, prolonging illnesses, and increasing mortality rates.<\/span><\/li>\n
- The lack of stringent oversight enables pharmaceutical companies to produce fixed-dose antibiotic combinations without proper clinical trials.<\/span><\/li>\n
- Examples<\/strong>: Nearly 64% of antibiotics sold in India are unapproved, fueling resistance. Surveys indicate that many Indian inpatients are prescribed multiple antibiotics, exacerbating AMR.<\/span><\/li>\n<\/ul>\n<\/li>\n
|
![\"GS](\"https:\/\/triumphias.com\/blog\/wp-content\/uploads\/2024\/12\/Blog-150x150.jpeg\")
<\/a><\/p>\n